Immune Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

FEATURES AND HIGHLIGHTS

News

13-Valent Pneumococcal Conjugate Vaccine Proves Favorable Safety Profile

PCV 13, a 13-valent pneumococcal conjugate vaccine, showed a favorable safety profile and immunogenicity when administered concomitantly with DTaP, a report at at IDWeek 2012 demonstrated.

5555 Tetravalent Dengue Vaccine Formulation Elicits Highest Immunogenicity

Results from a Phase 2 study reported on at IDWeek 2012 showed that the 5555 formulation of tetravalent dengue vaccine elicits the highest serpositivity rates and balanced response against all four serotypes with a satisfactory safety profile.

AAIC: IV Immunoglobulin Stabilizes Alzheimer's Symptoms

Alzheimer's disease (AD) symptoms stabilize among patients treated with intravenous immunoglobulin (IVIG) for 36 months.

Featured courses from mycme

Paid Activity

Immunizations Part 2, An Analysis of Vaccine Safety External web site

The goal of this program is to improve management of immunizations and to review safety concerns. This program is from the 2011 Scientific Assembly of the American Academy of Family Physicians.

2.00 AMA PRA Category 1 Credit(s)TM

New Drug Review from MPR May 2013 External web site

This activity will allow these healthcare professionals to make the most up-to-date—and most appropriate—therapeutic decisions for their patients.

1.00 AMA PRA Category 1 Credit(s)TM

A collaborative approach to myasthenia gravis External web site

From the December 2012 issue of The Clinical Advisor: A collaborative approach to myasthenia gravis. This chronic autoimmune disorder is caused by antibodies that block muscle cells from receiving neurotransmitters from the nerve cell.

0.50 AAPA Category I CME Credit
More myCME courses »